title: Pretreatment predictors of cognitive deficits in early psychosis.
abstract: BACKGROUND
  Predicting cognitive deficits in early psychosis may well be crucial to identify those individuals most in need of receiving intensive intervention. As yet, however, the identification of potential pretreatment predictors for cognitive performance has been hampered by inconsistent findings across studies. We aimed to examine the associations of functional and clinical pretreatment variables with cognitive functioning after a first psychotic episode.
  
  
  METHODS
  One hundred and thirty-one patients experiencing first-episode psychosis were assessed for psychopathology, pre-morbid functioning, duration of illness, age of onset, and family history of psychosis and neurocognitive functioning. Multiple regression analyses were conducted for six basic cognitive dimensions known to be affected in this population: verbal learning, verbal memory, verbal comprehensive abilities, executive functioning, motor dexterity and sustained attention.
  
  
  RESULTS
  Pre-morbid functioning was the main predictor for five out of the six basic cognitive domains. Pre-morbid social adjustment difficulties were associated with worse performance in executive functioning, motor dexterity and sustained attention. Academic functioning was associated with verbal comprehension, and verbal learning and memory. Gender, age of onset, duration of untreated psychosis, and family history of psychosis had no or limited value as predictors of neurocognitive outcome.
  
  
  CONCLUSIONS
  Poor pre-morbid functioning was related to a worse performance in the six basic cognitive dimensions evaluated; however, this accounted for only a small amount of the explained variance. Cognitive impairment is a prominent feature in patients with early psychosis regardless of favorable prognostic features such as short duration of illness, female gender, later age of onset, and non-family history of psychosis.
authors.affiliation: University Hospital Marqués de Valdecilla, Psychiatry Research Unit of Cantabria, Department of Psychiatry, School of Medicine, Santander, Spain. cgblanch@terra.es
authors.forename: C
authors.initials: C
authors.lastname: González-Blanch
authors.forename: B
authors.initials: B
authors.lastname: Crespo-Facorro
authors.forename: M
authors.initials: M
authors.lastname: Alvarez-Jiménez
authors.forename: J M
authors.initials: JM
authors.lastname: Rodríguez-Sánchez
authors.forename: J M
authors.initials: JM
authors.lastname: Pelayo-Terán
authors.forename: R
authors.initials: R
authors.lastname: Pérez-Iglesias
authors.forename: J L
authors.initials: JL
authors.lastname: Vázquez-Barquero
mesh_terms: D000208:Acute Disease; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011379:Prognosis; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D012917:Social Adjustment
chemical_list: D014150:Antipsychotic Agents